1
|
Chadha M, Shao T, Lit M, Gupta V, Zakashansky K, Zeligs K, Kolev V. Upfront boost to gross disease followed by elective pelvic radiation improves compliance to radiation therapy delivery metrics in locally advanced vulvar cancer. Gynecol Oncol Rep 2024; 52:101362. [PMID: 38495799 PMCID: PMC10940132 DOI: 10.1016/j.gore.2024.101362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2024] [Revised: 03/04/2024] [Accepted: 03/05/2024] [Indexed: 03/19/2024] Open
Abstract
Locally advanced cancer of the vulva (LACV) is commonly diagnosed in older women (>65 years), and is treated using combined multimodality therapy (CMT) that includes radiation therapy (RT). Compliance to optimal RT metrics, including completion of > 20 fractions, overall treatment duration of < 8 weeks (56 days), and < 1 week intra-treatment break is associated with better disease outcomes. However, published results note that a significant number of patients with LACV do not adhere to these metrics. The aim of our study is to evaluate whether a modified sequence of RT delivery, treating the localized boost volume upfront followed by the larger elective nodal volume is associated with improved compliance to optimal RT delivery metrics.
Collapse
Affiliation(s)
- M. Chadha
- Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, United States
| | - T. Shao
- Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
| | - M. Lit
- Division of Gynecology, Icahn School of Medicine at Mount Sinai, New York, United States
| | - V. Gupta
- Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, United States
| | - K. Zakashansky
- Division of Gynecology, Icahn School of Medicine at Mount Sinai, New York, United States
| | - K. Zeligs
- Division of Gynecology, Icahn School of Medicine at Mount Sinai, New York, United States
| | - V. Kolev
- Division of Gynecology, Icahn School of Medicine at Mount Sinai, New York, United States
| |
Collapse
|
2
|
Carideo Cunniff E, Sato Y, Mai D, Appleman VA, Iwasaki S, Kolev V, Matsuda A, Shi J, Mochizuki M, Yoshikawa M, Huang J, Shen L, Haridas S, Shinde V, Gemski C, Roberts ER, Ghasemi O, Bazzazi H, Menon S, Traore T, Shi P, Thelen TD, Conlon J, Abu-Yousif AO, Arendt C, Shaw MH, Okaniwa M. TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies. Cancer Res Commun 2022; 2:489-502. [PMID: 36923556 PMCID: PMC10010323 DOI: 10.1158/2767-9764.crc-21-0161] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Revised: 03/30/2022] [Accepted: 05/20/2022] [Indexed: 11/16/2022]
Abstract
Oncology therapies targeting the immune system have improved patient outcomes across a wide range of tumor types, but resistance due to an inadequate T-cell response in a suppressive tumor microenvironment (TME) remains a significant problem. New therapies that activate an innate immune response and relieve this suppression may be beneficial to overcome this hurdle. TAK-676 is a synthetic novel stimulator of interferon genes (STING) agonist designed for intravenous administration. Here we demonstrate that TAK-676 dose-dependently triggers activation of the STING signaling pathway and activation of type I interferons. Furthermore, we show that TAK-676 is a highly potent modulator of both the innate and adaptive immune system and that it promotes the activation of dendritic cells, natural killer cells, and T cells in preclinical models. In syngeneic murine tumor models in vivo, TAK-676 induces dose-dependent cytokine responses and increases the activation and proliferation of immune cells within the TME and tumor-associated lymphoid tissue. We also demonstrate that TAK-676 dosing results in significant STING-dependent antitumor activity, including complete regressions and durable memory T-cell immunity. We show that TAK-676 is well tolerated, exhibits dose-proportional pharmacokinetics in plasma, and exhibits higher exposure in tumor. The intravenous administration of TAK-676 provides potential treatment benefit in a broad range of tumor types. Further study of TAK-676 in first-in-human phase I trials is ongoing. Significance TAK-676 is a novel systemic STING agonist demonstrating robust activation of innate and adaptive immune activity resulting in durable antitumor responses within multiple syngeneic tumor models. Clinical investigation of TAK-676 is ongoing.
Collapse
Affiliation(s)
| | - Yosuke Sato
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | - Doanh Mai
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | - Vicky A Appleman
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | - Shinji Iwasaki
- Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa, Japan
| | - Vihren Kolev
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | - Atsushi Matsuda
- Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa, Japan
| | - Judy Shi
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | | | | | - Jian Huang
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | - Luhua Shen
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | - Satyajeet Haridas
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | - Vaishali Shinde
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | - Chris Gemski
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | - Emily R Roberts
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | - Omid Ghasemi
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | - Hojjat Bazzazi
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | - Saurabh Menon
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | - Tary Traore
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | - Pu Shi
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | - Tennille D Thelen
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | - Joseph Conlon
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | - Adnan O Abu-Yousif
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | - Christopher Arendt
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | - Michael H Shaw
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| | - Masanori Okaniwa
- Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
| |
Collapse
|
3
|
Vyskocil S, Cardin D, Ciavarri J, Conlon J, Cullis C, England D, Gershman R, Gigstad K, Gipson K, Gould A, Greenspan P, Griffin R, Gulavita N, Harrison S, Hu Z, Hu Y, Hata A, Huang J, Huang SC, Janowick D, Jones M, Kolev V, Langston SP, Lee HM, Li G, Lok D, Ma L, Mai D, Malley J, Matsuda A, Mizutani H, Mizutani M, Molchanova N, Nunes E, Pusalkar S, Renou C, Rowland S, Sato Y, Shaw M, Shen L, Shi Z, Skene R, Soucy F, Stroud S, Xu H, Xu T, Abu-Yousif AO, Zhang J. Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route. J Med Chem 2021; 64:6902-6923. [PMID: 34000802 DOI: 10.1021/acs.jmedchem.1c00374] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Stimulator of Interferon Genes (STING) plays an important role in innate immunity by inducing type I interferon production upon infection with intracellular pathogens. STING activation can promote increased T-cell activation and inflammation in the tumor microenvironment, resulting in antitumor immunity. Natural and synthetic cyclic dinucleotides (CDNs) are known to activate STING, and several synthetic CDN molecules are being investigated in the clinic using an intratumoral administration route. Here, we describe the identification of STING agonist 15a, a cyclic dinucleotide structurally diversified from natural ligands with optimized properties for systemic intravenous (iv) administration. Our studies have shown that STING activation by 15a leads to an acute innate immune response as measured by cytokine secretion and adaptive immune response via activation of CD8+ cytotoxic T-cells, which ultimately provides robust antitumor efficacy.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Robert Skene
- Drug Discovery Sciences, Takeda Pharmaceuticals International Company, 9625 Towne Centre Drive, San Diego, California 92121, United States
| | | | | | | | | | | | | |
Collapse
|
4
|
Gill C, Tomita S, Suhner J, D'Andrea M, Umphlett M, Blank S, Tsankova N, Shrivastava R, Fowkes M, Kolev V. Tumor infiltrating lymphocytes in brain metastases from gynecological malignancies. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
5
|
Holtzman S, Finkelstein M, Huntly J, Kolev V, Zakashansky K. Regional trends of minimally invasive radical hysterectomy for cervical cancer and exploration of perioperative outcomes. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Kossl K, Rosen L, Copperman A, Kolev V, Zakashansky K. 37: Use of colpotomy for contained tissue extraction during laparoscopic myomectomy. Am J Obstet Gynecol 2020. [DOI: 10.1016/j.ajog.2019.12.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
7
|
Suhner J, Tomita S, Kolev V. Retroperitoneal Lymph Nodes: Cytoreduction in a Patient with Ovarian Cancer. J Minim Invasive Gynecol 2019. [DOI: 10.1016/j.jmig.2019.09.527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
8
|
Wood K, Bui A, Alexander S, Howell E, Kolev V, Blank S, Chadha M. Factors influencing time interval between diagnosis and primary surgical management of endometrial cancer. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.04.299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
9
|
Rosen L, Finkelstein M, Murphy K, Fenske S, Kolev V, Ascher-Walsh C, Zakashansky K. 62: Robotic-assisted laparoscopy versus conventional laparoscopy for the treatment of endometriosis in New York state, 2009-2016. Am J Obstet Gynecol 2019. [DOI: 10.1016/j.ajog.2019.01.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
10
|
Maniuc O, Fischer G, Petri N, Sakas G, Kolev V, Nordbeck P, Herrmann S, Frantz S, Voelker W. P3422High precision vessel access during transfemoral aortic valve implantation - a pilot study of puncture guidance using a new navigation technique. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- O Maniuc
- University Hospital of Wurzburg, Department of Internal Medicine I, Wurzburg, Germany
| | - G Fischer
- University Hospital of Wurzburg, Department of Internal Medicine I, Wurzburg, Germany
| | - N Petri
- University Hospital of Wurzburg, Department of Internal Medicine I, Wurzburg, Germany
| | | | | | - P Nordbeck
- University Hospital of Wurzburg, Department of Internal Medicine I, Wurzburg, Germany
| | - S Herrmann
- University Hospital of Wurzburg, Department of Internal Medicine I, Wurzburg, Germany
| | - S Frantz
- University Hospital of Wurzburg, Department of Internal Medicine I, Wurzburg, Germany
| | - W Voelker
- University Hospital of Wurzburg, Department of Internal Medicine I, Wurzburg, Germany
| |
Collapse
|
11
|
Schwartz M, Li S, Nair N, Orfanelli T, Kolev V, Liu Y, Kalir T, Dottino P, Blank S. A new era: Changing patterns of high-grade serous fallopian tube cancer diagnosis. Gynecol Oncol 2018. [DOI: 10.1016/j.ygyno.2018.04.430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
12
|
Schwartz M, Kolev V, Nair N, Orfanelli T, Blank S, Kalir T, Dottino P, Liu Y. Neoadjuvant chemotherapy for gynecologic high-grade serous carcinoma: Correlation of tumor response with tumor morphology and immunophenotype. Gynecol Oncol 2018. [DOI: 10.1016/j.ygyno.2018.04.379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
13
|
Amidon BS, Wu D, Bradley J, Ma J, Tsu C, Carideo-Cunniff E, Kolev V, Garnsey J, Shah P, Koenig E, Liao H, Cullis C. Abstract 1493: LonP1 is required for tumor maintenance and growth. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-1493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Proper mitochondrial function is critical for energy production and the cycling of metabolites required for tumor establishment and growth. LonP1 is an ATP-dependent serine protease that is critical for maintaining mitochondrial protein homeostasis by degrading misfolded and damaged proteins in the mitochondrial matrix. Knockdown of LonP1 has been shown to reduce tumorogenesis and is consistent with the model that requires properly functioning mitochondria for tumor establishment. It is unclear what the role of LonP1 is in tumor maintenance and growth from an established tumor, therefore the LonP1 gene was mutated and complemented by a doxycycline-inducible copy of LonP1. These complementation clones have the ability to establish tumors in vivo in the presence of doxycycline, however upon doxycycline withdrawal the tumors regress and show evidence of apoptosis. These xenograft lines permit unique insight into not only potential LonP1 substrates but also the direct and indirect effects from loss of mitochondrial matrix protein homeostasis. Comparison and contrast of these complemented cell lines in vitro and in vivo by expression and proteomic analysis will be discussed.
Citation Format: Benjamin S. Amidon, Dongyun Wu, John Bradley, Jingya Ma, Christopher Tsu, Elizabeth Carideo-Cunniff, Vihren Kolev, James Garnsey, Pooja Shah, Erik Koenig, Hua Liao, Courtney Cullis. LonP1 is required for tumor maintenance and growth [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1493. doi:10.1158/1538-7445.AM2017-1493
Collapse
Affiliation(s)
| | - Dongyun Wu
- Takeda Pharmaceuticals, Inc, Cambridge, MA
| | | | - Jingya Ma
- Takeda Pharmaceuticals, Inc, Cambridge, MA
| | | | | | | | | | - Pooja Shah
- Takeda Pharmaceuticals, Inc, Cambridge, MA
| | | | - Hua Liao
- Takeda Pharmaceuticals, Inc, Cambridge, MA
| | | |
Collapse
|
14
|
Pereira E, Nair N, Schwartz M, Gorski J, Dottino P, Kolev V, Gupta V. Patterns of care for FIGO stage IB-IIA cervical cancer across the United States. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
15
|
Pereira E, Nair N, Gorski J, Schwartz M, Zakashansky K, Dottino P, Kolev V, Hayes M. The addition of chemotherapy to adjuvant radiotherapy in patients with intermediate-risk stage IB cervical cancer and the effect on survival. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
16
|
Bean L, Sulzmaier F, Anderson K, Tancioni I, Kolev V, Plaxe S, McHale M, Schlaepfer D, Pachter J. Focal adhesion kinase (FAK) inhibition overcomes cisplatin-resistance in epithelial ovarian cancer. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.229] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
17
|
Nair N, Pereira E, Schwartz M, Zakashansky K, Hayes M, Dottino P, Kolev V. Thirty-day hospital readmission and mortality in advanced uterine cancer. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
Pereira E, Kolev V, Gaigbe-Togbe B, Rahaman J, Hayes M, Pearlman-Shapiro M. Chemotherapy and radiotherapy for the adjuvant treatment of uterine papillary serous carcinoma. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
19
|
Falk K, Andikyan V, Kolev V. Laparoscopic Resection of Para-Aortic Tumor Recurrence Using Kocher Maneuver Duodenal Mobilization. J Minim Invasive Gynecol 2016. [DOI: 10.1016/j.jmig.2016.08.417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
20
|
Chadha M, Guo G, Kolev V, Kalach N, Bernstein K, Cohen S, Koulos J. Experience Using 3 Fractions of 8 Gy High-Dose-Rate Brachytherapy Once a Week Following Chemoradiation Therapy in Clinical Node-Negative Cervix Cancer. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1365] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
21
|
Madeira da Silva L, Scalici J, McClellan S, Laurini J, Cruthirds L, Kolev V, Li Y, Shapiro I, Weaver D, Rocconi R. Standard chemotherapy for ovarian cancer increases expression of cancer stem cell biomarkers which is predictive of survival. Gynecol Oncol 2016. [DOI: 10.1016/j.ygyno.2016.04.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
22
|
Chadha M, Domi M, Parikh R, Kolev V, Koulos J. The time interval of adjuvant radiation therapy is influenced by the primary surgical technique used in treatment of endometrial cancer. Gynecol Oncol 2016. [DOI: 10.1016/j.ygyno.2016.04.524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Mandelberger A, Andikyan V, Kolev V. 21: Laparoscopic radical hysterectomy for stage IIA1 cervical cancer. Am J Obstet Gynecol 2016. [DOI: 10.1016/j.ajog.2016.01.134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
24
|
Kanis MJ, Kolev V, Getrajdman J, Zakashansky K, Cohen C, Rahaman J. Carcinosarcoma of the ovary: a single institution experience and review of the literature. EUR J GYNAECOL ONCOL 2016; 37:75-79. [PMID: 27048114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
PURPOSE To evaluate the management and outcome in patients with advanced stage primary carcinosarcoma (CS) of the ovary in a single institution. MATERIALS AND METHODS The authors performed a retrospective analysis of all patients treated for CS of the ovary between 1994 and 2011. The medical records, operative reports and pathology records were abstracted for baseline characteristics, surgical staging, degree of cytoreduction and chemotherapy regimens used. Standard statistical methods for analysis of the data were used. RESULTS A total of 33 patients with ovarian CS were identified. Of these, 28 records were available for analysis. One patient was Stage I (3.5%), two were Stage II (11.1%), 20 were Stage III (71.4%), and five (17.9%) were Stage IV. The early stage (Stage I and II) patients were excluded from analysis. Of the 25 advanced stage (III and IV) patients, 21 (84.0%) were optimally cytoreduced to a residual disease of < one cm and four (16.0%) were suboptimally cytoreduced. The median progression free survival (PFS) and overall survival (OS) were ten and 21 months, respectively, for advanced stages. Twenty-one (75%) patients received adjuvant chemotherapy and 62% (13 of 21) of treated patients received paclitaxel/carboplatin (T/C) as first-line chemotherapy. The median PFS and OS were 15.6 and 31.7 months, respectively, for those treated with T/C. There was no.difference in PFS (p = 0.42) and OS (p = 0.91) between the patients who received T/C vs. other chemotherapy regimens as a first-line adjuvant chemotherapy. Patients with optimal cytoreduction had an improved PFS compared to those with suboptimal cytoreduction (ten vs. four monthsp = 0.015); however, there was no difference in OS (21 vs. 13 p = 0.117). The two-year OS was 48.0%. In the preset study, PFS was improved in patients who were optimally cytoreduced at the time of diagnosis. CONCLUSION T/C is an active regimen in the treatment of ovarian CS and has the potential to be the backbone for addition of biologic targeted therapies in the future. For advanced ovarian CS the authors recommend optimal cytoreductive surgery followed by T/C chemotherapy.
Collapse
|
25
|
Kanis MJ, Rahaman J, Moshier EL, Zakashansky K, Chuang L, Kolev V. Detection and correlation of pre-operative, frozen section, and final pathology in high-risk endometrial cancer. EUR J GYNAECOL ONCOL 2016; 37:338-341. [PMID: 27352560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
PURPOSE To evaluate sensitivity and specificity of pre-operative and frozen section pathologic evaluation (FSA) in predicting high-risk (HR) histology endometrial cancer. MATERIALS AND METHODS A retrospective analysis was performed on all patients diagnosed with endometrial cancer at a single institution. Medical records were abstracted for baseline characteristics, surgical reports for staging, and final histology was confirmed by a gynecologic pathologist. RESULTS 868 patients were identified. Of these, 118 had Grade 3 endometrioid, 36 clear cell carcinoma (CCC), 47 carcinosarcoma (CS), and 84 uterine papillary serous carcinoma (UPSC) histology. Endometrial biopsy (EMB) had an overall sensitivity of 90%, 77% for low grade, 78% for HR, with a specificity of 0%. For dilation and curettage (D&C), overall sensitivity was 85%, 69% for low grade, and 77% for HR. Specificity was 33%. Sensitivities for combined pre-operative testing for G3 endometrioid, CCC, CS, and UPSC were: 56%, 28%, 72%, and 60%, respectively. For frozen section analysis (FSA), overall sensitivity was 77%, and 67% for low and high grade. For G3 endometrioid, CCC, CS, and UPSC, sensitivities were 57%, 20%, 74%, 32%, respectively. Specificity was 95%. FSA identified an additional six patients (8%) with UPSC, CCC or CS that were pre-operatively low risk, providing an 8% improvement in sensitivity but decreased specificity. CONCLUSIONS Pre-operative EMB and D&C are overall very sensitive for detecting endometrial cancer; however, sensitivity decreases with HR histology. Pre-op testing will miss 28% of HR diagnoses and FSA provides an opportunity to identify some patients with UPSC, CCC, and CS. If pre-operative results suggest HR cancer, the surgeon should proceed with comprehensive surgical staging without an FSA.
Collapse
|
26
|
Farag S, Andikyan V, Fields J, Kanis M, Rahaman J, Kolev V, Hayes M. Clinical Outcomes of Type II Endometrial Cancer in Open Versus Minimally Invasive Staging Surgery. J Minim Invasive Gynecol 2015; 22:S229. [DOI: 10.1016/j.jmig.2015.08.806] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
27
|
Kolev V, Wang Y, Sprott K, Padval M, Pachter J, Weaver D. 281 VS-5584, a dual PI3K/mTOR inhibitor, demonstrates robust activity in pre-clinical models of SCLC with the inhibition of both cancer stem cells and bulk tumor cells. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30166-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
28
|
Shapiro I, Kolev V, Wang Y, Padval M, Baas P, Bueno R, Pachter J, Weaver D. 280 FAK inhibitor defactinib (VS-6063) targets mesothelioma cancer stem cells: Rationale for maintenance therapy after conventional chemotherapy. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30165-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
29
|
Hiraki M, Hwang SY, Cao S, Ramadhar TR, Byun S, Yoon KW, Lee JH, Chu K, Gurkar AU, Kolev V, Zhang J, Namba T, Murphy ME, Newman DJ, Mandinova A, Clardy J, Lee SW. Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis. ACTA ACUST UNITED AC 2015; 22:1206-16. [PMID: 26320861 DOI: 10.1016/j.chembiol.2015.07.016] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2015] [Revised: 06/26/2015] [Accepted: 07/08/2015] [Indexed: 12/31/2022]
Abstract
TP53 is the most frequently mutated gene in human cancer, and small-molecule reactivation of mutant p53 function represents an important anticancer strategy. A cell-based, high-throughput small-molecule screen identified chetomin (CTM) as a mutant p53 R175H reactivator. CTM enabled p53 to transactivate target genes, restored MDM2 negative regulation, and selectively inhibited the growth of cancer cells harboring mutant p53 R175H in vitro and in vivo. We found that CTM binds to Hsp40 and increases the binding capacity of Hsp40 to the p53 R175H mutant protein, causing a potential conformational change to a wild-type-like p53. Thus, CTM acts as a specific reactivator of the p53 R175H mutant form through Hsp40. These results provide new insights into the mechanism of reactivation of this specific p53 mutant.
Collapse
Affiliation(s)
- Masatsugu Hiraki
- Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
| | - So-Young Hwang
- Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
| | - Shugeng Cao
- Department of Pharmaceutical Sciences, Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, 34 Rainbow Drive, Hilo, HI 96720, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
| | - Timothy R Ramadhar
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
| | - Sanguine Byun
- Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
| | - Kyoung Wan Yoon
- Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
| | - Jung Hyun Lee
- Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
| | - Kiki Chu
- Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
| | - Aditi U Gurkar
- Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
| | - Vihren Kolev
- Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
| | - Jianming Zhang
- Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
| | - Takushi Namba
- Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
| | - Maureen E Murphy
- Program in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA 19104, USA
| | - David J Newman
- Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
| | - Anna Mandinova
- Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Jon Clardy
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
| | - Sam W Lee
- Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
| |
Collapse
|
30
|
Pereira E, De B, Kolev V, Zakashansky K, Green S, Dottino P, Gupta V. Survey of current practice patterns in the treatment of early stage endometrial cancer among SGO members. Gynecol Oncol 2015. [DOI: 10.1016/j.ygyno.2015.01.374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
31
|
Prada F, Del Bene M, Mattei L, Lodigiani L, DeBeni S, Kolev V, Vetrano I, Solbiati L, Sakas G, DiMeco F. Preoperative magnetic resonance and intraoperative ultrasound fusion imaging for real-time neuronavigation in brain tumor surgery. Ultraschall Med 2015; 36:174-186. [PMID: 25429625 DOI: 10.1055/s-0034-1385347] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
PURPOSE Brain shift and tissue deformation during surgery for intracranial lesions are the main actual limitations of neuro-navigation (NN), which currently relies mainly on preoperative imaging. Ultrasound (US), being a real-time imaging modality, is becoming progressively more widespread during neurosurgical procedures, but most neurosurgeons, trained on axial computed tomography (CT) and magnetic resonance imaging (MRI) slices, lack specific US training and have difficulties recognizing anatomic structures with the same confidence as in preoperative imaging. Therefore real-time intraoperative fusion imaging (FI) between preoperative imaging and intraoperative ultrasound (ioUS) for virtual navigation (VN) is highly desirable. We describe our procedure for real-time navigation during surgery for different cerebral lesions. MATERIALS AND METHODS We performed fusion imaging with virtual navigation for patients undergoing surgery for brain lesion removal using an ultrasound-based real-time neuro-navigation system that fuses intraoperative cerebral ultrasound with preoperative MRI and simultaneously displays an MRI slice coplanar to an ioUS image. RESULTS 58 patients underwent surgery at our institution for intracranial lesion removal with image guidance using a US system equipped with fusion imaging for neuro-navigation. In all cases the initial (external) registration error obtained by the corresponding anatomical landmark procedure was below 2 mm and the craniotomy was correctly placed. The transdural window gave satisfactory US image quality and the lesion was always detectable and measurable on both axes. Brain shift/deformation correction has been successfully employed in 42 cases to restore the co-registration during surgery. The accuracy of ioUS/MRI fusion/overlapping was confirmed intraoperatively under direct visualization of anatomic landmarks and the error was < 3 mm in all cases (100 %). CONCLUSION Neuro-navigation using intraoperative US integrated with preoperative MRI is reliable, accurate and user-friendly. Moreover, the adjustments are very helpful in correcting brain shift and tissue distortion. This integrated system allows true real-time feedback during surgery and is less expensive and time-consuming than other intraoperative imaging techniques, offering high precision and orientation.
Collapse
Affiliation(s)
- F Prada
- Neurosurgery, Fondazione IRCCS Istituto Neurologico C. Besta, Milano, Italy
| | - M Del Bene
- Neurosurgery, Fondazione IRCCS Istituto Neurologico C. Besta, Milano, Italy
| | - L Mattei
- Neurosurgery, Fondazione IRCCS Istituto Neurologico C. Besta, Milano, Italy
| | - L Lodigiani
- Research and Development, Esaote S. p. a., Genova, Italy
| | - S DeBeni
- Research and Development, Esaote S. p. a., Genova, Italy
| | - V Kolev
- Research and Development, MedCom, Darmstadt, Germany
| | - I Vetrano
- Neurosurgery, Fondazione IRCCS Istituto Neurologico C. Besta, Milano, Italy
| | - L Solbiati
- Interventional Oncology, A. O. Circolo, Busto Arsizio, Italy
| | - G Sakas
- Research and Development, MedCom, Darmstadt, Germany
| | - F DiMeco
- Neurosurgery, Fondazione IRCCS Istituto Neurologico C. Besta, Milano, Italy
| |
Collapse
|
32
|
Andikyan V, Tabrizian P, Farag S, Fields J, Kolev V, Rahaman J, Fishman D, Sarpel U, Zakashansky K, Labow D. Hyperthermic intraperitoneal chemotherapy for treatment of ovarian and primary peritoneal cancer: Single institutional experience. Gynecol Oncol 2015. [DOI: 10.1016/j.ygyno.2015.01.434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
33
|
Liu L, Barbi A, Kolev T, Kolev V. Sentinel Lymph Node Mapping for Endometrial Cancer: A Contemporary Approach to Surgical Staging. J Minim Invasive Gynecol 2014. [DOI: 10.1016/j.jmig.2014.08.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
34
|
Lee JH, Chen H, Kolev V, Aull KH, Jung I, Wang J, Miyamoto S, Hosoi J, Mandinova A, Fisher DE. High-throughput, high-content screening for novel pigmentation regulators using a keratinocyte/melanocyte co-culture system. Exp Dermatol 2014; 23:125-9. [PMID: 24438532 DOI: 10.1111/exd.12322] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/13/2014] [Indexed: 01/06/2023]
Abstract
Skin pigmentation is a complex process including melanogenesis within melanocytes and melanin transfer to the keratinocytes. To develop a comprehensive screening method for novel pigmentation regulators, we used immortalized melanocytes and keratinocytes in co-culture to screen large numbers of compounds. High-throughput screening plates were subjected to digital automated microscopy to quantify the pigmentation via brightfield microscopy. Compounds with pigment suppression were secondarily tested for their effects on expression of microphthalmia transcription factor (MITF) and several pigment regulatory genes, and further validated in terms of non-toxicity to keratinocytes/melanocytes and dose-dependent activity. The results demonstrate a high-throughput, high-content screening approach, which is applicable to the analysis of large chemical libraries using a co-culture system. We identified candidate pigmentation inhibitors from 4000 screened compounds including zoxazolamine, 3-methoxycatechol and alpha-mangostin, which were also shown to modulate expression of MITF and several key pigmentation factors and are worthy of further evaluation for potential translation to clinical use.
Collapse
Affiliation(s)
- Ju Hee Lee
- Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Dermatology, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Zhu Z, Todorova K, Lee KK, Wang J, Kwon E, Kehayov I, Kim HG, Kolev V, Dotto GP, Lee SW, Mandinova A. Small GTPase RhoE/Rnd3 is a critical regulator of Notch1 signaling. Cancer Res 2014; 74:2082-93. [PMID: 24525741 DOI: 10.1158/0008-5472.can-12-0452] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Aberrations of Notch signaling have been implicated in a variety of human cancers. Oncogenic mutations in NOTCH1 are common in human T-cell leukemia and lymphomas. However, loss-of-function somatic mutations in NOTCH1 arising in solid tumors imply a tumor suppressor function, which highlights the need to understand Notch signaling more completely. Here, we describe the small GTPase RhoE/Rnd3 as a downstream mediator of Notch signaling in squamous cell carcinomas (SCC) that arise in skin epithelia. RhoE is a transcriptional target of activated Notch1, which is attenuated broadly in SCC cells. RhoE depletion suppresses Notch1-mediated signaling in vitro, rendering primary keratinocytes resistant to Notch1-mediated differentiation and thereby favoring a proliferative cell fate. Mechanistic investigations indicated that RhoE controls a key step in Notch1 signaling by mediating nuclear translocation of the activated portion of Notch1 (N1IC) through interaction with importins. Our results define RhoE as a Notch1 target that is essential for recruitment of N1IC to the promoters of Notch1 target genes, establishing a regulatory feedback loop in Notch1 signaling. This molecular circuitry may inform distinct cell fate decisions to Notch1 in epithelial tissues, where carcinomas such as SCC arise.
Collapse
Affiliation(s)
- Zehua Zhu
- Authors' Affiliations: Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown; Broad Institute of Harvard and MIT, Cambridge Center, Massachusetts; Institute of Immunology, Sofia, Bulgaria; and Department of Biochemistry, University of Lausanne, Epalinges, Switzerland
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Mauri G, De Beni S, Forzoni L, D'Onofrio S, Kolev V, Laganà MM, Solbiati L. Virtual navigator automatic registration technology in abdominal application. Annu Int Conf IEEE Eng Med Biol Soc 2014; 2014:5570-5574. [PMID: 25571257 DOI: 10.1109/embc.2014.6944889] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Real-time Ultrasound (US) image fusion with a pre-acquired second imaging dataset - Computed Tomography (CT), Magnetic Resonance Imaging (MRI) and/or CT/PET - has become widely used in recent years for both diagnosis and image-guided interventional procedures. Liver and kidneys are the main focused anatomical districts, related to abdominal application. There are still nowadays some drawbacks, regarding the adoption of the fusion imaging technique in everyday practice especially regarding its ease of use and the time needed in order to obtain a precise real-time fusion between US and the second imaging modality. The present work is a preliminary study on the feasibility and practical use of an Automatic registration algorithm for CT-US real-time fusion imaging. Data obtained by tests performed on a Doppler phantom, for the assessment of the precision of the registration procedure and in-vivo Automatic registration tests, are presented.
Collapse
|
37
|
Silverman Fenske S, Soto E, Astill N, Kolev V, Friedman K, Moshier E, El Hachem L, Chuang L, Gretz H. Comparison of the Incidence of Vaginal Cuff Dehiscence with Laparoscopic Continuous Unidirectional Barbed Suture Closure Versus Interrupted Polyglactin Closure. J Minim Invasive Gynecol 2013. [DOI: 10.1016/j.jmig.2013.08.150] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
38
|
Kolev V, Wright Q, Vidal C, Shapiro I, Pavdal M, Keegan M, Xu Q, Pachter J. Abstract 236: Pharmacological and genetic inhibition of FAK attenuates cancer stem cell function in vitro and in vivo. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that orchestrates cell signaling through integrins and growth factor receptors. FAK has been implicated in multiple steps of carcinogenesis including tumor initiation, growth and metastasis. Amplification and overexpression of FAK have been observed in multiple aggressive human cancers including breast and ovarian. VS-4718 is a potent and selective FAK kinase inhibitor that was previously shown by us to exhibit preferential inhibitory activities on breast cancer stem cells. We have further extended our investigation of the role of FAK on cancer stem cells to other solid tumors and report here that pharmacological attenuation of FAK activity by VS-4718 or RNAi-mediated depletion of FAK exhibits preferential inhibitory effects on cancer stem cells.
To determine if FAK plays a role in the biology of cancer stem cells, we depleted FAK expression in breast, ovarian and mesothelioma cancer cell lines by RNAi. Our results indicated that shRNA-mediated knock-down of FAK inhibits tumorsphere formation in vitro. In parallel, VS-4718 was evaluated in a multitude of cancer stem cell assays both in vitro and in vivo. Pre-treatment of SUM159 cells with VS-4718 in matrigel reduced the percentage of ALDEFLUOR+ cancer stem cells and side population (SP). Similar effects were observed in ovarian cancer cell lines OVCAR-8 and OVCAR-5 where VS-4718 inhibited cancer stem cells as measured by multiple CSC assays. In an analogous fashion, VS-4718 also reduced the proportion of the ALDEFLUOR+ cells in H2052 human mesothelioma cells. In direct contrast, standard-of-care agents paclitaxel, carboplatin or pemetrexed increased the percentage of cancer stem cells, suggesting these agents do not effectively target cancer stem cells. Importantly combination of VS-4718 with standard-of-care agents attenuated chemotherapy-induced increases in the percentage of cancer stem cells in vitro in all three cancer models.
The in vivo effect of VS-4718 on cancer stem cells was evaluated in SUM159 and MDA-MB-231 human triple negative breast cancer xenograft models. Following systemic administration, VS-4718 significantly reduced the proportion of cancer stem cells in tumors as evidenced by decreases in the percentage of ALDEFLUOR+ cells and tumorsphere-forming efficiency relative to vehicle-treated tumors and significantly abrogated tumor-initiating capabilities of cancer cells in a limiting dilution re-implantation assay.
In summary, our results indicate the importance of FAK in the self-renewal of cancer stem cells in vitro and in vivo, and support the clinical development of FAK inhibitors to target cancer stem cells for the treatment of multiple cancers.
Citation Format: Vihren Kolev, Quentin Wright, Christian Vidal, Irina Shapiro, Mahesh Pavdal, Mitchell Keegan, Qunli Xu, Jonathan Pachter. Pharmacological and genetic inhibition of FAK attenuates cancer stem cell function in vitro and in vivo. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 236. doi:10.1158/1538-7445.AM2013-236
Collapse
|
39
|
Kolev V, Mandinova A, Guinea-Viniegra J, Hu B, Lefort K, Lambertini C, Neel V, Dummer R, Wagner EF, Dotto GP. Erratum: EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat Cell Biol 2012. [DOI: 10.1038/ncb2676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
40
|
Cardenas Goicoechea J, Shephard A, Momeni M, Kolev V, Davis A, Rahaman J, Gretz H, Randall T, Chuang L. Survival and Operative Outcome Analysis of Robotic Assisted Versus Laparoscopic Surgical Staging for Endometrial Cancer. J Minim Invasive Gynecol 2012. [DOI: 10.1016/j.jmig.2012.08.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
41
|
Silverman Fenske S, Kolev V, Gretz H. Radical Parametrectomy. J Minim Invasive Gynecol 2012. [DOI: 10.1016/j.jmig.2012.08.547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
42
|
Momeni M, Kolev V, Cardenas Goicoechea J, Getrajdman J, Fishman D, Chuang L, Kalir T, Rahaman J, Zakashansky K. Does the Type of Surgery for Early-Stage Endometrial Cancer Affect the Rate of Reported Lymph Vascular Invasion in Final Pathology Specimens? J Minim Invasive Gynecol 2012. [DOI: 10.1016/j.jmig.2012.08.598] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
Forzoni L, D’Onofrio S, Beni SD, Laganà MM, Kolev V, Baselli G, Ciuti G, Righi D. Virtual Navigator Tridimensional Panoramic Imaging in Transcranial Application. BIOMED ENG-BIOMED TE 2012. [DOI: 10.1515/bmt-2012-4282] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
| | | | | | - M. M. Laganà
- MRI Laboratory, Fondazione Don Carlo Gnocchi ONLUS, IRCCS S. Maria Nascente, Milano, Italy
| | | | - G. Baselli
- Dipartimento di Bioingegneria, Politecnico di Milano, Milano, Italy
| | - G. Ciuti
- Medical and Surgical Critical Care Department, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy
| | - D. Righi
- Angiology Department, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy
| |
Collapse
|
44
|
Kolev V, Ruseva MM, Hughes TR, Donev RM, Paul Morgan B. Targeting C/EBPβ sensitises tumours to killing via complement-dependent and complement-independent mechanisms. Mol Immunol 2011. [DOI: 10.1016/j.molimm.2011.06.372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
45
|
Kolev V, Zhang R, Bradley W, N'gouamba R, Dottino P, Rahaman J, Hayes M. Sequential chemotherapy and radiation therapy for the adjuvant treatment of uterine papillary serous carcinoma. Gynecol Oncol 2011. [DOI: 10.1016/j.ygyno.2010.12.224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
46
|
Verleger R, Yordanova J, Kolev V, Wagner U, Born J. Gesteigerte α- (8-12Hz) Aktivität während slow-wave sleep als Marker für den Übergang von impliziter Kenntnis zu expliziter Einsicht. KLIN NEUROPHYSIOL 2011. [DOI: 10.1055/s-0031-1272667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
47
|
Mandinova A, Kolev V, Neel V, Hu B, Stonely W, Lieb J, Wu X, Colli C, Han R, Pazin MJ, Pazin M, Ostano P, Dummer R, Brissette JL, Dotto GP. A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. J Clin Invest 2010; 119:3127-37. [PMID: 19729838 DOI: 10.1172/jci38543] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2009] [Accepted: 07/01/2009] [Indexed: 01/01/2023] Open
Abstract
Seborrheic keratoses (SKs) are common, benign epithelial tumors of the skin that do not, or very rarely, progress into malignancy, for reasons that are not understood. We investigated this by gene expression profiling of human SKs and cutaneous squamous cell carcinomas (SCCs) and found that several genes previously connected with keratinocyte tumor development were similarly modulated in SKs and SCCs, whereas the expression of others differed by only a few fold. In contrast, the tyrosine kinase receptor FGF receptor-3 (FGFR3) and the transcription factor forkhead box N1 (FOXN1) were highly expressed in SKs, and close to undetectable in SCCs. We also showed that increased FGFR3 activity was sufficient to induce FOXN1 expression, counteract the inhibitory effect of EGFR signaling on FOXN1 expression and differentiation, and induce differentiation in a FOXN1-dependent manner. Knockdown of FOXN1 expression in primary human keratinocytes cooperated with oncogenic RAS in the induction of SCC-like tumors, whereas increased FOXN1 expression triggered the SCC cells to shift to a benign SK-like tumor phenotype, which included increased FGFR3 expression. Thus,we have uncovered a positive regulatory loop between FGFR3 and FOXN1 that underlies a benign versus malignant skin tumor phenotype.
Collapse
Affiliation(s)
- Anna Mandinova
- Cutaneous Biology Research Center, Massachusetts General Hospital (MGH), Charlestown, Massachusetts, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Garcia-Garcia M, Yordanova J, Kolev V, Dominguez-Borras J, Escera C. Tuning the brain for novelty detection under emotional threat: the role of specific gamma-band phase synchronization. Neuroimage 2009. [DOI: 10.1016/s1053-8119(09)70001-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
49
|
Kolev V, Mironov S, Mironov O, Moskowitz C, Ishill NM, Gardner GJ, Levine DA, Hricak H, Barakat RR, Chi DS. The prognostic significance of supradiaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced stage epithelial ovarian cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e16512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16512 Background: It has been hypothesized and shown in animal studies that the supradiaphragmatic lymph nodes serve as the principal nodes for lymphatic drainage of the entire peritoneal cavity. The purpose of this study was to determine the prognostic significance of enlarged supra-diaphragmatic nodes noted on preoperative computed tomography (CT) scan in patients with advanced epithelial ovarian cancer (EOC). Methods: We performed a retrospective chart review of all patients (pts) with FIGO stage III and IV EOC who had preoperative CT scans of the supradiaphragmatic region and primary cytoreductive surgery at our institution between 1997 and 2004. All scans were retrospectively reviewed by one board-certified radiologist (SM). To evaluate survival, Kaplan-Meier methods were used, with log rank Pvalues for comparisons. Results: A total of 212 eligible pts who underwent attempted primary cytoreduction followed by platinum-based systemic chemotherapy were identified for evaluation. With a median follow-up time of 52 mos, there were 135 deaths and a median overall survival of 48 mos (95% CI: 44–53). Of the 212 pts, 44 (21%) had supradiaphragmatic adenopathy with nodes >1 cm, while 168 (79%) did not have adenopathy in this distribution. None of the 44 pts with adenopathy had the enlarged nodes removed at primary cytoreduction. The median survival was 49 mos for pts with and 48 mos for patients without adenopathy (p = 0.46). In total, 155 (73%) patients underwent optimal cytoreduction (residual disease ≤ 1 cm). In the optimally cytoreduced pts, the median survival for the 125 pts without supradiaphragmatic adenopathy was 52 mos (95%CI: 45–59) compared to 51mos (95%CI: 41–58) for the 30 pts with supradiaphragmatic adenopathy (p = 0.33). Conclusions: Although a previous study has shown that supradiaphragmatic adenopathy was associated with poorer overall survival in EOC patients, our study did not confirm these findings. In our study, enlarged supradiaphragmatic nodes noted on preoperative CT scan did not have significant prognostic impact and therefore their clinical significance remains uncertain. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- V. Kolev
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S. Mironov
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - O. Mironov
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - C. Moskowitz
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - N. M. Ishill
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - G. J. Gardner
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - D. A. Levine
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - H. Hricak
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - R. R. Barakat
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - D. S. Chi
- Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
50
|
Chi D, Zivanovic O, Kolev V, Yu C, Levine DA, Sonoda Y, Abu-Rustum NR, Huh J, Barakat RR, Kattan MW. Nomogram for predicting 5-year survival after primary surgery for epithelial ovarian cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5523] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5523 Background: Nomograms have been shown to be superior to traditional staging systems for predicting an individual's probability of long-term survival. Our objective was to develop a nomogram based on established prognostic factors to predict the probability of 5-year disease-specific survival (DSS) after primary surgery for patients with epithelial ovarian cancer (EOC) and to compare its predictive accuracy with the currently used FIGO staging system. Methods: We identified all pts with EOC who had their primary staging/cytoreductive surgery at our institution from January 1996-December 2004. DSS was estimated using the Kaplan-Meier method. We analyzed 28 clinical and pathologic factors for prognostic significance. Significant factors on univariate analysis were then included in the Cox proportional hazards regression model, which identified the factors to be used to construct the nomogram. The concordance index (CI) was used as an accuracy measure, with bootstrapping to correct for optimistic bias. Calibration plots were constructed. Results: There were 478 evaluable pts on the study. The median age was 58 years (range 25–96). The primary surgeon in all cases was an attending gynecologic oncologist. All patients received platinum-based systemic chemotherapy postop. DSS at 5 years was 52%. The most predictive nomogram was constructed using the following 7 predictor variables: age, ASA status, family history suggestive of hereditary breast/ovarian cancer syndrome, preoperative serum albumin level, FIGO stage, tumor histology, and residual disease status after primary surgery. This nomogram was internally validated using bootstrapping and shown to have excellent calibration with a bootstrap-corrected CI of 0.721. The CI for FIGO staging alone was significantly less at 0.62 (p = 0.002). Conclusions: We developed a nomogram to predict 5-year DSS after primary surgery for EOC. The nomogram uses 7 variables that are readily accessible, assigns a point value to each variable, and then predicts the probability of 5-year survival based on the total point value for an individual patient. This tool is more accurate than FIGO staging and should be useful for patient counseling, clinical trial eligibility determination, postop management, and follow-up. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. Chi
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - O. Zivanovic
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - V. Kolev
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - C. Yu
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - D. A. Levine
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Y. Sonoda
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | | | - J. Huh
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - R. R. Barakat
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - M. W. Kattan
- Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|